Clinical bottom line
Novel immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but pose complex challenges in autoimmune disease management. While ICIs can exacerbate pre-existing autoimmune conditions or trigger de novo autoimmune phenomena, emerging evidence suggests potential roles for modulating immune checkpoints in treating autoimmune diseases. However, clinical application remains experimental, with careful risk-benefit assessment essential due to immune-related adverse events (irAEs).
What the evidence shows
ICIs targeting CTLA-4, PD-1, and PD-L1 pathways unleash antitumor immunity but may disrupt immune tolerance, precipitating autoimmune complications. Furukawa et al. (2021) reviewed effects of ICIs in cancer patients with pre-existing autoimmune diseases, reporting increased risk of disease flares and irAEs, though many cases were manageable with immunosuppression.
Duong et al. (2022) detailed paraneoplastic autoimmune neurological syndromes associated with ICIs, highlighting the complexity of immune modulation in autoimmunity and cancer.
Bagley et al. (2019) described diagnostic and management challenges of immune-related hypersensitivity pneumonitis, an autoimmune-like lung toxicity linked to ICIs, underscoring the need for multidisciplinary care.
Nanda et al. (2016) provided foundational insights into immunotherapy mechanisms, emphasizing the balance between antitumor efficacy and autoimmunity.
Maniar et al. (2023) discussed immunotherapy in thymic epithelial tumors, illustrating the nuanced interplay between tumor immunity and autoimmunity in this context.
Liu et al. (2025) performed integrated pan-cancer analyses revealing ADM’s role in immune modulation and resistance, suggesting potential novel checkpoint targets for autoimmune disease modulation.
Tan et al. (2026) reviewed cyclosporine’s mechanisms and emerging advances, relevant as immunosuppressive countermeasures in autoimmune toxicities from ICIs.
An epidemiologic analysis (unattributed source) documented frequencies of autoimmune-mediated adverse events with ICIs, reinforcing the need for vigilant monitoring.
Caveats and uncertainty
Most data derive from oncology cohorts, limiting direct applicability to primary autoimmune disease treatment.
ICI-induced autoimmunity mechanisms are incompletely understood, complicating therapeutic targeting.
Balancing immune activation for disease control against risk of irAEs remains challenging.
Long-term outcomes of modulating checkpoints in autoimmunity require further study.
No established protocols exist for using ICIs as primary autoimmune disease therapies.
How this may change practice
Clinicians should carefully evaluate autoimmune disease history before initiating ICIs, anticipating and monitoring for flares.
Multidisciplinary collaboration is critical for managing ICI-related autoimmune complications.
Emerging research may identify novel checkpoint targets for autoimmune disease modulation, potentially expanding therapeutic options.
Immunosuppressive strategies such as cyclosporine may mitigate irAEs without compromising antitumor efficacy.
Ongoing clinical trials and translational studies are needed to define safe and effective checkpoint modulation in autoimmunity.